Peppercorn Jeffrey, A Carey Lisa
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center CB# 7305, 3009 Old Clinic Chapel Hill, NC 27514, USA.
Expert Rev Anticancer Ther. 2008 Feb;8(2):191-4. doi: 10.1586/14737140.8.2.191.
Evaluation of: Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient Cyp2D6 and Cyp2c19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007). Tamoxifen is one of the most commonly used treatments for breast cancer but is not effective in all patients. We review the study by Schroth and colleagues, evaluating the correlation between genotype for CYP2D6 and other enzymes involved in tamoxifen metabolism and breast cancer outcome. This study demonstrates that patients treated with tamoxifen with intermediate and poor metabolism genotypes have a higher risk of relapse, independent of other prognostic factors. Patients who were not treated with tamoxifen had no differences in outcomes based on CYP2D6 status. This study adds to the growing body of literature suggesting that genetic differences in patients can determine the effectiveness of tamoxifen and highlights the need for studies evaluating how genotype can best guide selection of endocrine therapy for breast cancer.
施罗特W、安东尼阿杜L、弗里茨P等。辅助性他莫昔芬治疗乳腺癌的疗效与患者细胞色素P450 2D6（Cyp2D6）和细胞色素P450 2C19（Cyp2c19）基因型的关系。《临床肿瘤学杂志》，第25卷，5187 - 5193页（2007年）。他莫昔芬是最常用于治疗乳腺癌的药物之一，但并非对所有患者都有效。我们回顾了施罗特及其同事的研究，该研究评估了CYP2D6及其他参与他莫昔芬代谢的酶的基因型与乳腺癌治疗结果之间的相关性。这项研究表明，接受他莫昔芬治疗且代谢基因型为中等和较差的患者复发风险更高，且不受其他预后因素影响。未接受他莫昔芬治疗的患者，其治疗结果根据CYP2D6状态并无差异。这项研究为越来越多表明患者基因差异可决定他莫昔芬疗效的文献增添了内容，并突出了评估基因型如何能最佳指导乳腺癌内分泌治疗选择的研究的必要性。
